Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Pseudomonas aeruginosa Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea

다국어 초록 (Multilingual Abstract)

Background: Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) have been on the rise worldwide, and delayed active antimicrobial therapy is associated with high mortality. However, few studies have evaluated increases in P. aeruginosa infections with antimicrobial resistance and risk factors for such antimicrobial resistance in Korea. Here, we analyzed changes in antimicrobial susceptibility associated with P. aeruginosa bacteremia and identified risk factors of antimicrobial resistance.
Methods: The medical records of patients with P. aeruginosa bacteremia who were admitted to a tertiary hospital between January 2009 and October 2020 were retrospectively reviewed.
Antibiotic resistance rates were compared among the time periods of 2009–2012, 2013–2016, and 2017–2020 and between the intensive care unit (ICU) and non-ICU setting. Empirical antimicrobial therapy was considered concordant, if the organism was susceptible to antibiotics in vitro, and discordant, if resistant.
Results: During the study period, 295 patients with P. aeruginosa bacteremia were identified.
The hepatobiliary tract (26.8%) was the most common primary site of infection. The rates of carbapenem-resistant P. aeruginosa (CRPA), MDRPA, and extensively drug-resistant P. aeruginosa (XDRPA) were 24.7%, 35.9%, and 15.9%, respectively. XDRPA showed an increasing trend, and CRPA, MDRPA, and XDRPA were also gradually increasing in non-ICU setting. Previous exposure to fluoroquinolones and glycopeptides and urinary tract infection were independent risk factors associated with CRPA, MDRPA, and XDRPA. Previous exposure to carbapenems was an independent risk factor of CRPA. CRPA, MDRPA, and XDRPA were associated with discordant empirical antimicrobial therapy.
Conclusion: The identification of risk factors for antimicrobial resistance and analysis of antimicrobial susceptibility might be important for concordant empirical antimicrobial therapy in patients with P. aeruginosa bacteremia.

참고문헌 (Reference)

1 Singer M, "The third international consensus definitions for sepsis and septic shock(Sepsis-3)" 315 (315): 801-810, 2016

2 Aryee A, "The relationship between clinical outcomes and empirical antibiotic therapy in patients with community-onset gram-negative bloodstream infections : a cohort study from a large teaching hospital" 148 : e225-, 2020

3 Tuon FF, "Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy" 16 (16): 351-356, 2012

4 Jeong SJ, "Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa : clinical impact of bacterial virulence and strains on outcome" 80 (80): 130-135, 2014

5 Kim YJ, "Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy" 14 : 161-, 2014

6 Joo EJ, "Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia : clinical impact of antimicrobial resistance on outcome" 17 (17): 305-312, 2011

7 Montero MM, "Risk factors for mortality among patients with Pseudomonas aeruginosa bloodstream infections : What is the influence of XDR phenotype on outcomes" 9 (9): 514-, 2020

8 Raman G, "Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections : a systematic review and meta-analysis" 7 : 79-, 2018

9 Merchant S, "Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy : a systematic literature review and meta-analysis" 14 : 33-44, 2018

10 Lee CH, "Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems" 50 (50): 677-683, 2017

11 Kang CI, "Pseudomonas aeruginosa bacteremia : risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome" 37 (37): 745-751, 2003

12 Parkins MD, "Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection" 38 (38): 25-32, 2010

13 Clinical and Laboratory Standards Institute (CLSI), "Performance Standards for Antimicrobial Susceptibility Testing. 29th ed"

14 Korean Disease Control and Prevention Agency (KDCA), "National Antimicrobial Resistance Surveillance in Korea. 2019 Annual Report" KDCA 2020

15 Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance" 18 (18): 268-281, 2012

16 Aloush V, "Multidrug-resistant Pseudomonas aeruginosa : risk factors and clinical impact" 50 (50): 43-48, 2006

17 Korea Centers for Disease Control and Prevention (KCDC), "Korean Antimicrobial Resistance Monitoring System:KARMS 2016 Annual Report" KCDC 2018

18 Peña C, "Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections" 60 (60): 539-548, 2015

19 Tamma PD, "Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales(ESBL-E), carbapenem-resistant Enterobacterales(CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance(DTR-P. aeruginosa)" 72 (72): e169-e183, 2021

20 Kadri SS, "Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities : a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals" 21 (21): 241-251, 2021

21 Callejas-Díaz A, "Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: mortality and prognostic factors" 152 (152): 83-89, 2019

22 Korean National Healthcare-associated Infections Surveillance System (KONIS), "ICU reports"

23 Bassetti M, "How to manage Pseudomonas aeruginosa infections" 7 : 212527-, 2018

24 Revelas A, "Healthcare-associated infections : a public health problem" 53 (53): 59-64, 2012

25 Haque M, "Health care-associated infections-an overview" 11 : 2321-2333, 2018

26 Horcajada JP, "Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa Infections" 32 (32): e00031-19-, 2019

27 Palavutitotai N, "Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections" 13 (13): e0193431-, 2018

28 Kadri SS, "Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals : retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents" 67 (67): 1803-1814, 2018

29 Yo CH, "Clinical predictors and outcome impact of community-onset polymicrobial bloodstream infection" 54 (54): 716-722, 2019

30 Suárez C, "Clinical impact of imipenemresistant Pseudomonas aeruginosa bloodstream infections" 58 (58): 285-290, 2009

31 Nathwani D, "Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections : a systematic review and meta-analysis" 3 (3): 32-, 2014

32 Samonis G, "Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections" 42 (42): 721-728, 2014

33 Buehrle DJ, "Carbapenem-resistant Pseudomonas aeruginosa bacteremia : risk factors for mortality and microbiologic treatment failure" 61 (61): e01243-16-, 2016

34 Centers for Disease Control and Prevention (CDC), "CDC/NHSN surveillance definitions for specific types of infections"

35 Matuschek E, "Antimicrobial susceptibility testing of colistin-evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp" 24 (24): 865-870, 2018

36 Liu C, "Antimicrobial resistance in South Korea : a report from the Korean Global Antimicrobial Resistance Surveillance System(Kor-GLASS)for 2017" 25 (25): 845-859, 2019

37 Centers for Disease Control and Prevention (CDC), "Antibiotic resistance threats in the United States, 2019"

38 Centers for Disease Control and Prevention (CDC), "Antibiotic resistance threats in the United States, 2013"